Servagi Vernat Stéphanie, Ali David, Puyraveau Marc, Viard Romain, Lisbona Albert, Fenoglietto Pascal, Bedos Ludovic, Makovicka Libor, Giraud Philippe
Department of Radiation Oncology, Besançon University Hospital, Besançon, France; University of Franche Comté, IRMA/LCPR-AC/CE UMR 6249 CNRS, Montbéliard, France.
Paris Descartes University, Department of Radiation Oncology, Georges Pompidou European Hospital, Paris, France.
Phys Med. 2014 May;30(3):280-5. doi: 10.1016/j.ejmp.2013.07.128. Epub 2013 Aug 12.
Intensity Modulated Arc Therapy (IMAT) can be planned and delivered via several techniques. Advanced Radiotherapy (ARTORL) is a prospective study that aims to evaluate the treatment costs and clinical aspects of implementing these IMAT techniques for head and neck cancers. In this context, we evaluated the potential dosimetric gain of Helical Tomotherapy (TomoTherapy, Accuray, HT) versus VMAT (Rapid'Arc(®), Varian Medical System, RA) for oropharyngeal cancer (OC).
Thirty patients were selected from our database in whom bilateral neck irradiation and treatment to the primary were indicated. Each patient was planned twice using both HT and RA planning systems using a simultaneous integrated boost approach. For the planning target volumes (PTV) and organs at risk, ICRU 83 reporting guidelines were followed. RA and HT plans were compared using paired Student's t-test.
RA and HT produced plans with a good coverage of PTVs and acceptable sparing of OARs. Although some dosimetric differences were statistically significant, they remained small. However, the near maximal dose to the PRV of spinal cord and brain stem was lower with HT. Regarding normal tissue, HT increased the volume irradiated at doses between 4 and 20 Gy compared to RA.
In OC, HT and RA showed similar dosimetric results. They represent the maximum gains obtained with photon beams. The medicoeconomic evaluation of our study is ongoing and may reveal differences between these techniques in terms of MU number, fraction time, and clinical evaluation.
调强弧形放疗(IMAT)可通过多种技术进行计划和实施。高级放射治疗(ARTORL)是一项前瞻性研究,旨在评估对头颈部癌实施这些IMAT技术的治疗成本和临床情况。在此背景下,我们评估了螺旋断层放疗(TomoTherapy,Accuray公司,HT)与容积调强弧形放疗(VMAT,Varian医疗系统公司的Rapid'Arc(®),RA)治疗口咽癌(OC)的潜在剂量学获益。
从我们的数据库中选取30例需进行双侧颈部照射及原发灶治疗的患者。每位患者均使用HT和RA计划系统采用同步整合加量方法进行两次计划制定。对于计划靶区(PTV)和危及器官,遵循ICRU 83报告指南。使用配对t检验比较RA和HT计划。
RA和HT制定的计划对PTV的覆盖良好,对危及器官的保护可接受。尽管一些剂量学差异具有统计学意义,但差异仍然较小。然而,HT使脊髓和脑干的计划靶区内接近最大剂量更低。对于正常组织,与RA相比,HT增加了4至20 Gy剂量范围内照射的体积。
在口咽癌中,HT和RA显示出相似的剂量学结果。它们代表了光子束所能获得的最大获益。我们研究的医学经济学评估正在进行,可能会揭示这些技术在机器跳数、分次时间和临床评估方面的差异。